Physician profile
Sandra Collier
NPI 1760583686
$5,860.66
in general payments reported to CMS, 2019-2025
29 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,370 · 2022: $1,043 · 2023: $938 · 2024: $1,192 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,382 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,381.50 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $938.93 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $704.81 | 2021-2025 | |
| Lilly USA, LLC | $673.61 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $671.65 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $496.37 | 2021-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $366.23 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $266.61 | 2021-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.42 | 2021-2024 | Jardiance, Synjardy |
| Exact Sciences Corporation | $212.38 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $194.96 | 2023-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $181.01 | 2021-2022 | |
| Pfizer INC. | $180.49 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $160.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $127.92 | 2022-2025 | |
| Amarin Pharma, INC. | $122.47 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $56.48 | 2024-2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $40.52 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.61 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $21.25 | 2025 | |
| Pharmacosmos Therapeutics INC. | $21.02 | 2024 | Monoferric |
| Alexion Pharmaceuticals, INC. | $20.16 | 2022 | |
| Amgen INC. | $19.74 | 2024 | Prolia, Evenity |
| Inspire Medical Systems, INC. | $19.50 | 2025 | Inspire |
| Radius Health, INC. | $19.21 | 2025 | Tymlos |
| Idorsia Pharmaceuticals US INC | $17.87 | 2022 | |
| Seqirus USA INC | $14.49 | 2022 | |
| Cipher Pharmaceuticals US LLC | $14.04 | 2025 | Spinosad, Natroba |
| Cranial Technologies, INC | $13.55 | 2024 | Doc Band |
| Glaxosmithkline, LLC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.